FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091224905> ?p ?o ?g. }

• W2091224905 endingPage "311" @default.
• W2091224905 startingPage "304" @default.
• W2091224905 abstract "Article AbstractBackground: Cardiovascular disease (CVD) mortality in schizophrenia is more frequent than in the general population. Whether second-generation antipsychotics (SGAs) increase risk of CVD morbidity and mortality has yet to be determined. Method: We conducted a retrospective cohort study using an administrative database to identify patients with DSM-III- or DSM-IV-diagnosed schizophrenia, treated in Maryland, who started clozapine treatment (n†‰=†‰1,084) or were never treated with clozapine (initiated on risperidone; n†‰=†‰602) between 1994 and 2000. Deaths between 1994 and 2004 were identified by the Social Security Death Index, and death records were obtained. Results: During the 6- to 10-year follow-up period, there were 136 deaths, of which 43 were attributed to CVD. Cardiovascular disease mortality in patients aged younger than 55 years at medication start was approximately 1.1% (clozapine, 1.1%; risperidone, 1.0%) in both groups at 5 years and 2.7% (clozapine) and 2.8% (risperidone) at 10 years (χ21†‰=†‰0.12, P†‰=†‰.73). Patients who started treatment at ages ≥†‰55 years had CVD mortality of 8.5% (clozapine) and 3.6% (risperidone) at 5 years and 16.0% (clozapine) and 5.7% (risperidone) at 10 years (χ21†‰=†‰2.13, P†‰=†‰.144). In a Cox regression model, patients aged ≥†‰55 years were at greater risk of mortality than younger patients (hazard ratio†‰=†‰4.6, P†‰<†‰.001); whites were at greater risk than nonwhites (HR†‰=†‰2.1, P†‰=†‰.046); however, SGA treatment (HR†‰=†‰1.2; 95% CI, 0.6-2.4; P†‰=†‰.61) and sex (HR†‰=†‰0.9, P†‰=†‰.69) were not statistically significant predictors of CVD, nor was there a significant age × clozapine interaction (χ21†‰=†‰1.52, P†‰=†‰.22). Age-, race-, and gender-adjusted standardized mortality ratios were significantly elevated (clozapine, 4.70; 95% CI, 3.19-6.67; risperidone, 2.88; 95% CI, 1.38-5.30) compared to year 2000 rates for the Maryland general population but did not differ by antipsychotic group (χ21†‰=†‰1.42, P†‰=†‰.23). Conclusions: The risk of CVD mortality in schizophrenia does not differ between clozapine and risperidone in adults despite known differences in risk profiles for weight gain and metabolic side effects. However, we cannot rule out an increased risk of CVD mortality among those starting treatment at ages 55 years or older. Submitted: September 17, 2008; accepted January 2, 2009. Online ahead of print: January 12, 2010. Corresponding author: Deanna L. Kelly, PharmD, BCPP, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 21247, Baltimore, MD 21228 (dkelly@mprc.umaryland.edu)." @default.
• W2091224905 created "2016-06-24" @default.
• W2091224905 creator A5018010521 @default.
• W2091224905 creator A5027810206 @default.
• W2091224905 creator A5045314404 @default.
• W2091224905 creator A5050302735 @default.
• W2091224905 creator A5060475373 @default.
• W2091224905 creator A5073102053 @default.
• W2091224905 creator A5077670489 @default.
• W2091224905 creator A5085025467 @default.
• W2091224905 date "2010-01-12" @default.
• W2091224905 modified "2023-09-24" @default.
• W2091224905 title "Cardiovascular Disease Mortality in Patients With Chronic Schizophrenia Treated With Clozapine" @default.
• W2091224905 cites W113842342 @default.
• W2091224905 cites W133714800 @default.
• W2091224905 cites W1493671385 @default.
• W2091224905 cites W150965689 @default.
• W2091224905 cites W167467255 @default.
• W2091224905 cites W1955497802 @default.
• W2091224905 cites W1981024070 @default.
• W2091224905 cites W1985732394 @default.
• W2091224905 cites W1997984196 @default.
• W2091224905 cites W1998927910 @default.
• W2091224905 cites W1999070612 @default.
• W2091224905 cites W2010752367 @default.
• W2091224905 cites W2011758256 @default.
• W2091224905 cites W2016362292 @default.
• W2091224905 cites W2018972399 @default.
• W2091224905 cites W2025723728 @default.
• W2091224905 cites W2030065928 @default.
• W2091224905 cites W2031894898 @default.
• W2091224905 cites W2039605943 @default.
• W2091224905 cites W2048976140 @default.
• W2091224905 cites W2049409039 @default.
• W2091224905 cites W2054728525 @default.
• W2091224905 cites W2062359581 @default.
• W2091224905 cites W2072993766 @default.
• W2091224905 cites W2076047881 @default.
• W2091224905 cites W2081163911 @default.
• W2091224905 cites W2082486375 @default.
• W2091224905 cites W2083168772 @default.
• W2091224905 cites W2088293485 @default.
• W2091224905 cites W2089423711 @default.
• W2091224905 cites W2089671853 @default.
• W2091224905 cites W2092755340 @default.
• W2091224905 cites W2095869868 @default.
• W2091224905 cites W2096463856 @default.
• W2091224905 cites W2097031522 @default.
• W2091224905 cites W2099684724 @default.
• W2091224905 cites W2103980602 @default.
• W2091224905 cites W2106413152 @default.
• W2091224905 cites W2121711249 @default.
• W2091224905 cites W2143057693 @default.
• W2091224905 cites W2143241112 @default.
• W2091224905 cites W2144334285 @default.
• W2091224905 cites W2146701930 @default.
• W2091224905 cites W2149288810 @default.
• W2091224905 cites W2150154702 @default.
• W2091224905 cites W2154820798 @default.
• W2091224905 cites W2158448796 @default.
• W2091224905 cites W2163093342 @default.
• W2091224905 cites W2164320549 @default.
• W2091224905 cites W2166920921 @default.
• W2091224905 cites W2167032570 @default.
• W2091224905 cites W2167116216 @default.
• W2091224905 cites W2188391155 @default.
• W2091224905 cites W2737030549 @default.
• W2091224905 cites W3027366030 @default.
• W2091224905 cites W42862353 @default.
• W2091224905 cites W2249586559 @default.
• W2091224905 cites W2995133996 @default.
• W2091224905 doi "https://doi.org/10.4088/jcp.08m04718yel" @default.
• W2091224905 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3607426" @default.
• W2091224905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20079332" @default.
• W2091224905 hasPublicationYear "2010" @default.
• W2091224905 type Work @default.
• W2091224905 sameAs 2091224905 @default.
• W2091224905 citedByCount "76" @default.
• W2091224905 countsByYear W20912249052012 @default.
• W2091224905 countsByYear W20912249052013 @default.
• W2091224905 countsByYear W20912249052014 @default.
• W2091224905 countsByYear W20912249052015 @default.
• W2091224905 countsByYear W20912249052016 @default.
• W2091224905 countsByYear W20912249052017 @default.
• W2091224905 countsByYear W20912249052018 @default.
• W2091224905 countsByYear W20912249052019 @default.
• W2091224905 countsByYear W20912249052020 @default.
• W2091224905 countsByYear W20912249052021 @default.
• W2091224905 countsByYear W20912249052022 @default.
• W2091224905 crossrefType "journal-article" @default.
• W2091224905 hasAuthorship W2091224905A5018010521 @default.
• W2091224905 hasAuthorship W2091224905A5027810206 @default.
• W2091224905 hasAuthorship W2091224905A5045314404 @default.
• W2091224905 hasAuthorship W2091224905A5050302735 @default.
• W2091224905 hasAuthorship W2091224905A5060475373 @default.
• W2091224905 hasAuthorship W2091224905A5073102053 @default.
• W2091224905 hasAuthorship W2091224905A5077670489 @default.
• W2091224905 hasAuthorship W2091224905A5085025467 @default.

• next